Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra, Inc. (NYSE: PEN) is described in its public communications as the world’s leading thrombectomy company, with a portfolio focused on computer assisted vacuum thrombectomy (CAVT™) and related devices for serious vascular and neurovascular conditions. The Penumbra news feed on this page aggregates company announcements, clinical trial updates and capital markets communications that shape how investors and clinicians follow the PEN stock story.
Recent news includes the announcement of a definitive Agreement and Plan of Merger with Boston Scientific Corporation, under which a Boston Scientific subsidiary will merge with and into Penumbra, leaving Penumbra as a wholly owned subsidiary if the transaction closes. The joint press release details the planned cash-and-stock consideration and notes that, upon completion, Penumbra’s securities are expected to be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934.
Beyond M&A developments, Penumbra’s news flow features earnings releases and preliminary financial updates furnished via Form 8-K, outlining revenue trends, margins and non-GAAP measures such as constant currency revenue and adjusted EBITDA. These items provide context on the company’s operating performance and financial outlook as it continues to develop and commercialize thrombectomy and embolization technologies.
Penumbra also issues news around clinical research milestones. Notable examples include results from the pivotal STORM-PE randomized controlled trial, which evaluated CAVT using Penumbra’s Lightning Flash™ plus anticoagulation versus anticoagulation alone in acute intermediate-high risk pulmonary embolism. Company press releases describe superior reductions in right heart strain, thrombus burden and improvements in functional outcomes for patients treated with CAVT plus anticoagulation, with comparable safety profiles between treatment arms.
Additional news items cover leadership changes and investor relations activities, such as the appointment of a new company president and scheduled presentations at healthcare and investor conferences, including the J.P. Morgan Healthcare Conference and other sector events. These updates highlight how Penumbra’s management communicates with the investment community and discusses its clinical and commercial strategy.
By following this PEN news page, readers can review a consolidated stream of Penumbra’s press releases, transaction announcements, clinical trial disclosures and financial updates, all of which are sourced from official company communications and SEC-related materials.
Penumbra (NYSE: PEN) provided unaudited, preliminary results for Q4 and full year 2025. Q4 revenue is estimated at $383.0M–$384.8M (+21.4% to +22.0% YoY; +23.2% to +23.8% ex-China). Full-year revenue is estimated at $1,401.3M–$1,403.1M (+17.3% to +17.5% YoY; +24.7% to +24.9% ex-China). Gross margin is ~67.9%–68.1% for Q4 and 67.1% for FY2025. Income from operations is $56.9M–$60.4M (Q4) and $186.9M–$190.4M (FY), implying operating margins of 14.8%–15.7% (Q4) and 13.3%–13.6% (FY).
Boston Scientific (NYSE: BSX) agreed to acquire Penumbra (NYSE: PEN) in a cash-and-stock deal valuing Penumbra at $374 per share, implying an enterprise value of about $14.5 billion. Consideration is ~73% cash and ~27% stock, with a 3.8721 BSX share election per PEN share. Penumbra expects 2025 reported revenue of ~$1.4 billion (growth ~17.3%–17.5%) and Q4 growth ~21.4%–22.0%. Boston Scientific plans to finance roughly $11 billion of the cash portion with cash on hand and new debt. The deal is expected to close in 2026, subject to approvals, and to be mildly dilutive to adjusted EPS by $0.06–0.08 in year one, turning neutral/acc-retive thereafter.
Penumbra (NYSE: PEN) announced its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 6:45pm ET / 3:45pm PT.
A live webcast will be available on the company website under Investors > Events and Presentations and will remain accessible for at least two weeks after the event.
Penumbra (NYSE: PEN) will present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 8:00 AM ET / 5:00 AM PT. A live webcast will be available via the company’s investor Events and Presentations page at www.penumbrainc.com and will remain on the site for at least two weeks after the event.
Penumbra (NYSE: PEN) reported Q3 2025 revenue of $354.7 million, up 17.8% (16.9% constant currency) versus Q3 2024, with the U.S. representing 77.5% of sales. U.S. revenue rose 21.5%; U.S. thrombectomy sales were $192.0 million, up 18.5%. Gross profit was $240.4 million, or 67.8% gross margin. Income from operations was $48.8 million (13.8% operating margin) and net income was $45.9 million; adjusted EBITDA was $66.7 million (18.8% margin). SG&A increased to $168.9 million. The company raised full‑year 2025 revenue guidance to $1,375 million–$1,380 million (15%–16% growth) and reaffirmed U.S. thrombectomy growth guidance of 20%–21%. A conference call and webcast are scheduled for Nov 5, 2025 at 4:30 PM ET.
Penumbra (NYSE:PEN) announced STORM-PE randomized controlled trial results (Nov 3, 2025) showing that CAVT plus anticoagulation produced significantly greater improvements versus anticoagulation alone in patients with acute intermediate-high risk pulmonary embolism.
Key numeric findings: refined modified Miller score reduction 42.1% vs 15.6% (2.7x; P<0.001), mean heart rate 80.0 vs 86.4 bpm (P=0.022), 90-day six-minute walk 472m vs 376m (P=0.019) and 94% vs 75% predicted walk distance (P=0.022). Safety through 90 days was comparable with no device-related mortality.
Penumbra (NYSE: PEN) reported STORM-PE RCT results (Oct 27, 2025) showing computer assisted vacuum thrombectomy (CAVT) plus anticoagulation was superior to anticoagulation alone for intermediate-high risk pulmonary embolism.
Key results: 100 patients across 22 sites; greater mean reduction in RV/LV ratio at 48 hours (0.52 vs. 0.24; P<0.001); higher positive treatment effect rate (78.3% vs. 51.9%; P=0.011); comparable 7-day major adverse event rates (4.3% vs. 7.5%). Additional STORM-PE data to be presented at VEINS/VIVA (Nov 1-4, 2025).
Penumbra (NYSE: PEN) will host an investor event at the 2025 TCT Conference on October 26, 2025 from 4:00–5:00 PM PT / 7:00–8:00 PM ET to discuss the STORM-PE clinical trial with management and the STORM-PE steering committee. A live webcast will be available on the company's Investors > Events and Presentations page and remain on the site for at least two weeks after the event.
The company also scheduled its Q3 2025 earnings release and conference call for after market close on November 5, 2025, with the call at 4:30 PM ET. The press release with third-quarter financial results will be issued after market close the same day. The conference call dial-in is (888) 596-4144 (conference id: 6572573) and a webcast will be available on the same investor events page for at least two weeks.
Penumbra (NYSE:PEN) and several leading medical organizations announced findings from a comprehensive survey on venous thromboembolism (VTE) care management through their 'Get Out the Clot' campaign. The survey of nearly 270 healthcare professionals revealed significant inconsistencies in blood clot treatment protocols.
Key findings show that only 56% of interventional physicians believe their protocols provide clear direction for pulmonary embolism (PE) risk management, while just 39% feel protocols are clear for deep vein thrombosis (DVT) treatment. Notably, 73% of interventional physicians want expanded use of thrombectomy and computer-assisted vacuum thrombectomy (CAVT) at their hospitals for PE patients, citing benefits like reduced ICU stays (57%) and improved hemodynamics (55%).
The survey also highlighted that more than half of institutions lack formal response teams, and only 35% of physicians report treatment decisions are made by specialty consensus, indicating significant room for improvement in collaborative care approaches.
Penumbra (NYSE: PEN), a leading thrombectomy company, has appointed Shruthi Narayan as its new President, effective September 1, 2025. Narayan, who brings 20 years of medical device industry experience, will report to Adam Elsesser, who continues as chairman and CEO.
Previously serving as president of Penumbra's interventional business, Narayan joined the company in 2013 and has led significant growth in both neuro and vascular franchises. Her experience includes roles at Medtronic and extensive work in engineering, regulatory affairs, and cardiovascular sales.
FAQ
What is the current stock price of Penumbra (PEN)?
What is the market cap of Penumbra (PEN)?
